Literature DB >> 15975256

An evaluation of selected oral fluid point-of-collection drug-testing devices.

Dennis J Crouch1, J M Walsh, Ron Flegel, Leo Cangianelli, Jakub Baudys, Randy Atkins.   

Abstract

Point-of-collection oral fluids drug-testing devices are being marketed for a variety of medico-legal purposes where they may complement existing technologies and be used to detect drugs following recent ingestion. To assess the utility of these devices for use in drugged-driving investigations, we performed a laboratory evaluation of four devices and those results were published previously. In the study reported here, two more devices, Oratect(R) (Branan) and Uplink(R) (OraSure), were evaluated for their ability to detect amphetamines, cocaine, opiates, and cannabinoids. An additional device, Drugwipe (Securtec), was evaluated for the detection of cocaine and cannabinoids. Each of the devices was assessed for their ability to meet the manufacturers' claimed cutoff concentrations and to meet cutoffs proposed for federal workplace programs. In general, the Branan and OraSure devices detected amphetamine, methamphetamine, opiates, and cannabinoid metabolite (THC-COOH) well in the concentration ranges approximating those proposed by the Substance Abuse and Mental Health Services Administration (SAMHSA), but all three devices performed poorly in detecting Delta9-tetrahydrocannabinol (THC) at the proposed SAMHSA cutoff. The ability to accurately and reliably detect cocaine was dependent on the individual device, and the Branan and Securetec devices were more effective than OraSure at detecting parent cocaine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15975256     DOI: 10.1093/jat/29.4.244

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  8 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

Review 2.  Laboratory testing for prescription opioids.

Authors:  Michael C Milone
Journal:  J Med Toxicol       Date:  2012-12

3.  Performance evaluation of the DrugWipe® 5/5+ on-site oral fluid screening device.

Authors:  Anna Pehrsson; Tom Blencowe; Kari Vimpari; Antti Impinen; Teemu Gunnar; Pirjo Lillsunde
Journal:  Int J Legal Med       Date:  2010-07-23       Impact factor: 2.686

4.  Drug testing in oral fluid.

Authors:  Olaf H Drummer
Journal:  Clin Biochem Rev       Date:  2006-08

5.  On-site test for cannabinoids in oral fluid.

Authors:  Nathalie A Desrosiers; Dayong Lee; David M Schwope; Garry Milman; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-08-21       Impact factor: 8.327

6.  Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices.

Authors:  Nathalie A Desrosiers; Garry Milman; Damodara R Mendu; Dayong Lee; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2014-05-15       Impact factor: 4.142

Review 7.  Oral fluid testing for drugs of abuse.

Authors:  Wendy M Bosker; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-09-10       Impact factor: 8.327

8.  Experience of road and other trauma by the opiate dependent patient: a survey report.

Authors:  Albert S Reece
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.